You have full text access to this OnlineOpen article

Cancer

Cover image for Vol. 116 Issue 24

15 December 2010

Volume 116, Issue 24

Pages 5565–5800

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Thanks to Authors and Peer Reviewers
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Review Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Thanks to Authors and Peer Reviewers
    1. You have full text access to this OnlineOpen article
      Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration (pages 5568–5574)

      Hagop M. Kantarjian, Deborah Thomas, Farhad Ravandi, Stefan Faderl, Elias Jabbour, Guillermo Garcia-Manero, Sherry Pierce, Jianquin Shan, Jorge Cortes and Susan O'Brien

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25354

      In this analysis, the authors identified a subset of adults with acute lymphocytic leukemia in first salvage in which standard therapies were associated with an extremely poor outcome. The results also confirmed the importance of achieving a complete response to improve survival.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Thanks to Authors and Peer Reviewers
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      Estimating recurrences prevented from using trastuzumab in HER-2/neu–positive adjuvant breast cancer in the United States (pages 5575–5583)

      Mark D. Danese, Deepa Lalla, Melissa Brammer, Quan Doan and Kevin Knopf

      Article first published online: 23 AUG 2010 | DOI: 10.1002/cncr.25347

      Trastuzumab could prevent recurrent cancer in as many as 2800 of the estimated 7300 HER2+ women diagnosed each year with stage I to III breast cancer in whom optimal chemo- and hormonal therapy would not prevent recurrence. This has important clinical and economic implications.

    2. You have full text access to this OnlineOpen article
      Patient satisfaction with postmastectomy breast reconstruction : A comparison of saline and silicone implants (pages 5584–5591)

      Colleen M. McCarthy, Anne F. Klassen, Stefan J. Cano, Amie Scott, Nancy VanLaeken, Peter A. Lennox, Amy K. Alderman, Babak J. Mehrara, Joseph J. Disa, Peter G. Cordeiro and Andrea L. Pusic

      Article first published online: 8 NOV 2010 | DOI: 10.1002/cncr.25552

      Breast cancer patients who receive silicone breast implants report higher satisfaction with the results of reconstruction compared with those who receive saline implants. This information can be used to optimize shared medical decision-making by providing breast cancer survivors with a more accurate estimation of predicted outcomes and more individualized treatment choices.

    3. Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Evaluation of the Seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification (pages 5592–5598)

      Hye Seong Ahn, Hyuk-Joon Lee, Seokyung Hahn, Woo-Ho Kim, Kuhn Uk Lee, Takeshi Sano, Stephen B Edge and Han-Kwang Yang

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25550

      The seventh TNM staging system for gastric cancer of the American Joint Committee on Cancer/International Union Against Cancer, based on analysis of Korean, Japanese, and North American outcome data sets, was found to provide better detailed classification of prognosis than the sixth system, especially between T2 and T3 tumors and N1 and N2 tumors. However, further study is needed for the N3a and N3b classification.

    4. You have full text access to this OnlineOpen article
      Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer : National Cancer Institute of Canada Clinical Trials Group Study PA.3 (pages 5599–5607)

      Gilda da Cunha Santos, Neesha Dhani, Dongsheng Tu, Kayu Chin, Olga Ludkovski, Suzanne Kamel-Reid, Jeremy Squire, Wendy Parulekar, Malcolm J. Moore and Ming Sound Tsao

      Article first published online: 7 SEP 2010 | DOI: 10.1002/cncr.25393

      The role of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status and the effect of epidermal growth factor receptor (EGFR) gene copy number (GCN) were evaluated as predictive markers using mutation analysis and fluorescence in situ hybridization in a subset of patients with pancreatic cancer who had tissue samples available for analysis from the National Cancer Institute of Canada Clinical Trials Group PA.3 trial. The results indicated that EGFR GCN and KRAS mutation status do not have potential as markers for predicting a survival benefit from combined erlotinib plus gemcitabine as first-line treatment for advanced pancreatic carcinoma.

    5. You have full text access to this OnlineOpen article
      Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy : A multi-institutional study of 1290 patients (pages 5608–5618)

      Olivier Glehen, François N. Gilly, Florent Boutitie, Jean M. Bereder, François Quenet, Lucas Sideris, Baudouin Mansvelt, Gérard Lorimier, Simon Msika and Dominique Elias

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25356

      The authors studied a registry that included 1290 patients with nonovarian peritoneal carcinomatosis who underwent cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. The results indicated that this therapeutic strategy is capable of producing long-term survival and a cure for selected patients who have acceptable postoperative morbidity and mortality.

    6. You have full text access to this OnlineOpen article
      The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy (pages 5619–5627)

      Yuki Hayashi, Arlene M. Correa, Wayne L. Hofstetter, Ara A. Vaporciyan, David C. Rice, Garrett L. Walsh, Reza J. Mehran, Jeffrey H. Lee, Manoop S. Bhutani, Alexander Dekovich, Stephen G. Swisher and Jaffer A. Ajani

      Article first published online: 8 NOV 2010 | DOI: 10.1002/cncr.25745

      The authors reviewed 301 consecutive esophageal cancer patients who underwent surgery but received no adjunctive therapy. Patients were segregated into 2 subgroups by baseline body mass index (BMI): normal/low (<25 kg/m2) and overweight (≥25 kg/m2). In the high BMI group, there were more men (P < .001), fewer upper esophageal tumors (P = .021), lower baseline clinical stage (P = .006), and frequent esophageal adenocarcinoma (P < .001). Postoperative morbidity was similar in both groups with the exception of gastrointestinal complications (P = .016). The 5-year overall survival (OS) rates were 44% in the normal/low BMI group and 60% in the high BMI group (P = .017). High BMI is common in patients with esophageal cancer and the better OS/disease-free survival rates noted in patients with a high BMI is because of the diagnosis of low baseline clinical stage. Confirmation of these findings is warranted.

    7. Genitourinary Disease
      You have full text access to this OnlineOpen article
      Association of PAI-1 gene polymorphism with survival and chemotherapy-related vascular toxicity in testicular cancer (pages 5628–5636)

      Esther C. de Haas, Nynke Zwart, Coby Meijer, Albert J.H. Suurmeijer, Karina Meijer, Henk-Jan Guchelaar, Harald J. Hoekstra, Flora E. van Leeuwen, Dirk Th. Sleijfer, H. Marike Boezen and Jourik A. Gietema

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25300

      In this study the common 4G/4G variant of PAI-1 4G/5G gene polymorphism is associated with reduced cancer-related survival in testicular cancer patients treated with platinum-based chemotherapy. This observation suggests that PAI-1 (4G/5G polymorphism) may be an additional biomarker in testicular cancer and contribute to the identification of patients who are at increased risk of not responding to standard chemotherapy.

    8. You have full text access to this OnlineOpen article
      MicroRNA-205–directed transcriptional activation of tumor suppressor genes in prostate cancer (pages 5637–5649)

      Shahana Majid, Altaf A. Dar, Sharanjot Saini, Soichiro Yamamura, Hiroshi Hirata, Yuichiro Tanaka, Guoren Deng and Rajvir Dahiya

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25488

      MicroRNA-205 functions as a tumor suppressor by up-regulating the interleukin (IL) tumor suppressor genes IL24 and IL32 and targeting specific sites in their promoters. The identification this phenomenon in which cancer cells can be targeted with microRNA to turn on silenced tumor suppressor genes may have significant therapeutic potential in the treatment of prostate cancer.

    9. You have full text access to this OnlineOpen article
      Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer (pages 5650–5658)

      Thomas Zilli, Miguel Chagnon, Thu Van Nguyen, Jean-Paul Bahary, Jean-Pierre Guay, Alix Dufresne and Daniel Taussky

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25539

      This study examined whether abdominal fat distribution provided a more objective and precise measure of the relation between obesity and pathologic features of prostate cancer. Greater abdominal adiposity was associated with adverse pathologic features in patients with localized prostate cancer and represented a strong risk factor for secondary malignancies.

    10. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia (pages 5659–5666)

      Gloria N. Mattiuzzi, Jorge E. Cortes, Deborah A. Blamble, B. Nebiyou Bekele, Lianchun Xiao, Maria Cabanillas, Gautam Borthakur, Susan O'Brien and Hagop Kantarjian

      Article first published online: 31 AUG 2010 | DOI: 10.1002/cncr.25365

      Nausea and vomiting in acute myelogenous leukemia (AML) patients can be from various causes, including the use of high-dose cytarabine. This study, the first prospective randomized trial of medications for the prevention of chemotherapy-induced nausea and vomiting in AML or high-risk myelodysplastic syndrome patients, suggests that palonosetron given daily for up to 5 days significantly reduced the incidence and severity of nausea on Days 6 and 7.

    11. You have full text access to this OnlineOpen article
      Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients (pages 5667–5675)

      Pier Luigi Zinzani, Alessandro Broccoli, Vittorio Stefoni, Gerardo Musuraca, Elisabetta Abruzzese, Amalia De Renzo, Maria Cantonetti, Francesco Bacci, Michele Baccarani and Stefano A. Pileri

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25307

      This study investigated the role of immunohistochemical discrimination between germinal center B-cell (GCB) and activated B-cell and not classified (ABC&NC) diffuse large B-cell lymphoma (DLBCL) subtypes in identifying those high-risk patients who may benefit from a more aggressive first-line therapeutic approach. The authors determined that an autologous stem cell transplantation consolidation in the ABC&NC-DLBCL subtypes induces the same rate of complete response and similar progression-free survival rate compared with GCB-DLBCL. In ABC&NC-DLBCL patients, the authors observed a complete response rate of 89.7% versus 84.6% reported in GCB-DLBCL subset, without any significant difference in progression-free survival rate.

    12. Lung Disease
      You have full text access to this OnlineOpen article
      Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer : Coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival (pages 5676–5685)

      Tom Donnem, Sigve Andersen, Khalid Al-Shibli, Samer Al-Saad, Lill-Tove Busund and Roy M. Bremnes

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25551

      Notch ligands and receptors have different impact in squamous cell carcinomas and adenocarcinomas in nonsmall cell lung cancer. Notch signaling plays a key role in angiogenesis, and the coexpression of Notch-1/vascular endothelial growth factor-A has a major impact on survival.

    13. You have full text access to this OnlineOpen article
      A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer : North Central Cancer Treatment Group Study N0326 (pages 5686–5693)

      Grace K. Dy, Shauna L. Hillman, Kendrith M. Rowland Jr, Julian R. Molina, Preston D. Steen, Donald B. Wender, Suresh Nair, Sumithra Mandrekar, Steven E. Schild and Alex A. Adjei

      Article first published online: 31 AUG 2010 | DOI: 10.1002/cncr.25448

      Sorafenib is not effective as front-line therapy in the general unselected nonsmall cell lung cancer population.

    14. You have full text access to this OnlineOpen article
      Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma (pages 5694–5699)

      Meredith Giuliani, Alexander Sun, Andrea Bezjak, Clement Ma, Lisa W. Le, Anthony Brade, John Cho, Natasha B. Leighl, Frances A. Shepherd and Andrew J. Hope

      Article first published online: 27 AUG 2010 | DOI: 10.1002/cncr.25341

      The authors explore the use of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. The reasons why patients do not receive prophylactic cranial irradiation and patients who are less likely to receive this treatment are reported.

    15. You have full text access to this OnlineOpen article
      Genetic variants in one-carbon metabolism-related genes contribute to NSCLC prognosis in a Chinese population (pages 5700–5709)

      Guangfu Jin, Jinlin Huang, Zhibin Hu, Juncheng Dai, Rong Tang, Yijiang Chen, Lin Xu, Xinen Huang, Yongqian Shu and Hongbing Shen

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25301

      MTR rs3768160 A>G, MTRR rs2966952 G>A, DHFR rs1650697 G>A, and MTHFD1 rs1950902 G>A were associated with nonsmall cell lung cancer (NSCLC) prognosis, which indicates that genetic variants in the one-carbon metabolism pathway may be candidate biomarkers for NSCLC prognosis.

    16. You have full text access to this OnlineOpen article
      Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer : Final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124 (pages 5710–5715)

      Primo N. Lara Jr, Kari Chansky, Taro Shibata, Haruhiko Fukuda, Tomohide Tamura, John Crowley, Mary W. Redman, Ronald Natale, Nagahiro Saijo and David R Gandara

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25532

      In the current era of clinical trial globalization, special consideration of differences in tumor biology, patient demographics, toxicity, and efficacy is essential. In this pooled comparative outcomes analysis of 2 major randomized clinical trials (of identical design) in extensive stage small cell lung cancer, a common arm approach revealed unique insights into this lethal disease and the relevance of multinational trials.

    17. Melanoma
      You have full text access to this OnlineOpen article
      Characteristics of the coexistence of melanoma and renal cell carcinoma (pages 5716–5724)

      Eve Maubec, Valérie Chaudru, Hamida Mohamdi, Florent Grange, Jean-Jacques Patard, Stéphane Dalle, Béatrice Crickx, Brigitte Bressac-de Paillerets, Florence Demenais and Marie-Françoise Avril

      Article first published online: 31 AUG 2010 | DOI: 10.1002/cncr.25562

      Clinical, pathologic, and phenotypic characteristics of 42 patients who had coexisting melanoma and renal cell carcinoma were compared with the characteristics of patients from 2 published French series that were ascertained systematically, including a series of 293 patients with melanoma and a series of 1527 patients with renal cell carcinoma. In addition to a high frequency of phenotypic risk factors for melanoma (pigmentation and nevus phenotypes), the most prominent features of the association between melanoma and renal cell carcinoma observed in this study were a high aggregation of cancers (mainly skin cancers) in the same patient and an excess of familial clustering of melanoma, which strongly argued for an inherited genetic predisposition.

    18. Neuro-Oncology
      You have full text access to this OnlineOpen article
      Incidence of atypical teratoid/rhabdoid tumors in children : A population-based study by the Austrian Brain Tumor Registry, 1996-2006 (pages 5725–5732)

      Adelheid Woehrer, Irene Slavc, Thomas Waldhoer, Harald Heinzl, Nadine Zielonke, Thomas Czech, Martin Benesch, Johannes A. Hainfellner and Christine Haberler

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25540

      A population-based series of malignant, high-grade brain tumors in children reveals an age-standardized incidence rate of 1.38 per 1,000,000 person-years for atypical teratoid/rhabdoid tumors, with a particularly high incidence noted in very young children (aged <3 years). Increased awareness of this high incidence in young children might help to optimize diagnostic and therapeutic management of patients with atypical teratoid/rhabdoid tumors.

    19. Sarcoma
      You have full text access to this OnlineOpen article
      Management of acral myxoinflammatory fibroblastic sarcoma (pages 5733–5739)

      Ajay Tejwani, Wendy Kobayashi, Yen-Lin Evelyn Chen, Andrew E. Rosenberg, Sam Yoon, Kevin A. Raskin, Daniel I. Rosenthal, Gunnlaugur P. Nielsen, Francis J. Hornicek and Thomas F. DeLaney

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25567

      Acral myxoinflammatory fibroblastic sarcoma (AMFS) is a rare, low-grade sarcoma that commonly affects the distal extremities. Data on 17 patients are consistent with local control of distal extremity sarcomas with resection and radiotherapy, suggesting that limb-sparing surgery with this combination treatment method is an appropriate option in the limb-sparing control of patients with AMFS, even those with positive margins.

    20. Discipline

      Disparities Research
      You have full text access to this OnlineOpen article
      Prevalence, predictors, and characteristics of off-treatment fatigue in breast cancer survivors (pages 5740–5748)

      Michael A. Andrykowski, Kristine A. Donovan, Christine Laronga and Paul B. Jacobsen

      Article first published online: 23 AUG 2010 | DOI: 10.1002/cncr.25294

      Prevalence, predictors, and characteristics of off-treatment cancer-related fatigue (CRF) in breast cancer survivors are identified. Results support a cognitive behavioral model of CRF and NCCN fatigue screening guidelines.

    21. Pathology
      You have full text access to this OnlineOpen article
      Cell type-dependent biomarker expression in adenoid cystic carcinoma : Biologic and therapeutic implications (pages 5749–5756)

      Diana Bell, Dianna Roberts, Merrill Kies, Pulivarthi Rao, Randal S. Weber and Adel K. El-Naggar

      Article first published online: 7 SEP 2010 | DOI: 10.1002/cncr.25541

      The authors of this report hypothesized that the dual cellular composition of adenoid cystic carcinoma (ACC) plays an important role in biomarker evaluation, tumor biologic behavior, and response to therapy. The current findings underscored the importance of accessing the differential localizations of different biomarkers in myoepithelial and ductal cells of ACC in the biologic evaluations and therapeutic stratification of this entity.

    22. Radiation Oncology
      You have full text access to this OnlineOpen article
      Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort (pages 5757–5766)

      David Schreiber, Justin Rineer, James B. Yu, Michelle Olsheski, Emmanuel Nwokedi, David Schwartz, Kwang Choi and Marvin Rotman

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25561

      This large population-based study detailed the risk of extraprostatic extension and positive margins in a broad setting across multiple regions and communities, as well as the use of adjuvant radiation for these patients. As of 2006, approximately 11.1% of patients who had indications for adjuvant radiation received this treatment, providing a useful baseline for future patterns of care studies.

    23. Symptom Control and Palliative Care
      You have full text access to this OnlineOpen article
      Symptom burden and performance status in a population-based cohort of ambulatory cancer patients (pages 5767–5776)

      Lisa Barbera, Hsien Seow, Doris Howell, Rinku Sutradhar, Craig Earle, Ying Liu, Audra Stitt, Amna Husain, Jonathan Sussman and Deborah Dudgeon

      Article first published online: 8 NOV 2010 | DOI: 10.1002/cncr.25681

      This is the first study to report Edmonton Symptom Assessment System (ESAS) and Palliative Performance Scale (PPS) scores in a large, geographically based cohort with a full scope of cancer diagnoses, including patients treated for cure. In this ambulatory cancer population, the high prevalence of numerous symptoms parallels those reported in palliative populations and represents a target for improved clinical care; it also sets the groundwork for future research on patient and provider outcomes using linked administrative healthcare data.

    24. Translational Research
      You have full text access to this OnlineOpen article
      Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma (pages 5777–5788)

      Wen-Chun Chang, Chao-Hsu Li, Su-Cheng Huang, Daw-Yuan Chang, Li-Yun Chou and Bor-Ching Sheu

      Article first published online: 23 AUG 2010 | DOI: 10.1002/cncr.25371

      Regulatory T cells in the tumor microenvironment may abrogate CD8+ T cell cytotoxicity in a granzyme B- and perforin-dependent conduit. Of clinical significance, the expression of regulatory T cells in tumor-infiltrating lymphocytes may mediate T cell immune repression within cancer milieu and thus greatly correlate with cancer progression.

  4. Thanks to Authors and Peer Reviewers

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Thanks to Authors and Peer Reviewers
    1. You have free access to this content

SEARCH

SEARCH BY CITATION